Results 81 to 90 of about 13,568,693 (193)

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, Volume 183, Issue 14, Page 3935-3949, July 2026.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

N, N-dimethyltryptamine forms oxygenated metabolites via CYP2D6 - an in vitro investigation

, 2023
N, N-dimethyltryptamine (DMT) is a psychedelic compound that has shown potential in the treatment of depression. Aside from the primary role of monoamine oxidase A (MAO-A) in DMT metabolism, the metabolic pathways are poorly understood.
Alicia Macan-Schönleben (17344598), Emma Eckernäs (17299396), Sofia Birgersson (17344604), Kurt-Jürgen Hoffmann (17344607), Moa Andresen-Bergström (17344601), Michael Ashton (1400944)   +5 more
core   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, Volume 183, Issue 14, Page 3897-3919, July 2026.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

British Journal of Pharmacology, Volume 183, Issue 14, Page 4058-4071, July 2026.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley, Gary Gilmour, Frederick Westhorpe, Grant Churchill, Trevor Sharp   +6 more
wiley   +1 more source

Contextual and experiential aspects of the psychedelic experience predicting improvement in subjective wellbeing: results from a Norwegian internet convenience sample

Frontiers in Pharmacology
BackgroundInterest in the therapeutic effects of classical psychedelics has risen recently. However, little epidemiological knowledge exists about the use of classical psychedelics in Scandinavian countries. Additionally, there is a limited understanding
Paula Aarseth Tunstad, Tor-Morten Kvam, Tor-Morten Kvam, Malin V. Uthaug, Malin V. Uthaug, Lowan H. Stewart, Kristoffer A. A. Andersen, Cato Grønnerød   +7 more
doaj   +1 more source

Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?

British Journal of Pharmacology, Volume 183, Issue 14, Page 4006-4021, July 2026.
Psychedelic drugs that activate 5‐HT2A receptors have been long used for cultural, medicinal and recreational purposes. Interest in psychedelics for treating psychiatric disorders has resurged recently and is well documented; less well recognised are their anti‐inflammatory properties. Growing evidence now demonstrates that psychedelics modulate immune
Omar Qureshi, Jamie Cowley, Ashley Pegg, Alison J. Cooper, John Gordon, Catherine A. Brady, Antonio Belli, Sam Butterworth, Rachel Upthegrove, Nick Andrews, Nicholas M. Barnes   +10 more
wiley   +1 more source

A SYSTEMATIC REVIEW OF RESEARCH ON N,N-DIMETHYLTRYPTAMINE

, 2017
Introduction: The effects of the endogenous hallucinogen N,N-dimethyltryptamine are poorly understood and its medical significance is widely unknown. A small number of  studies regarding its biochemical, pharmaceutical and physiological role have been ...
Hristova, Denitsa, Zhelyazkova-Savova, Maria   +1 more
core   +1 more source

The endogenous hallucinogen and trace amine N,N-dimethyltryptamine (DMT) displays potent protective effects against hypoxia via sigma-1 receptor activation in human primary iPSC-derived cortical neurons and microglia-like immune cells

Frontiers in Neuroscience, 2016
N,N-dimethyltryptamine (DMT) is a potent endogenous hallucinogen present in the brain of humans and other mammals. Despite extensive research, its physiological role remains largely unknown.
Attila Szabo, Attila Szabo, Attila Szabo, Attila Kovacs, Jordi Riba, Jordi Riba, Srdjan Djurovic, Srdjan Djurovic, Eva Rajnavolgyi, Ede Frecska   +9 more
doaj   +1 more source

Network control energy reductions under DMT relate to serotonin receptors, signal diversity, and subjective experience

Communications Biology
Psychedelics offer a profound window into the human brain through their robust effects on perception, subjective experience, and brain activity patterns.
S. Parker Singleton, Christopher Timmermann, Andrea I. Luppi, Emma Eckernäs, Leor Roseman, Robin L. Carhart-Harris, Amy Kuceyeski   +6 more
doaj   +1 more source

Effects of iproniazid and tranylcypromine on the half-life of N,N-dimethyltryptamine in rat brain and liver [PDF]

, 1976
The time course of N,N-dimethyltryptamine (DMT) levels in brain and liver of adult male Holtzman rats was determined with and without pretreatment with the monoamine oxidase inhibitors iproniazid (32 mg/kg) and tranylcypromine (10 mg/kg) given i.p.
Lu, L. J. Wang, Domino, Edward F.
core   +1 more source